Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
Last trade$1.49
Day change-$0.12 (-7.45%)
Day range$1.46 – $1.60
Volume12,482
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ADGM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ADGM.
Recent news
Company coverage with links to the original publishers.
Adagio Medical Holdings (NASDAQ: ADGM) stock surged 11.92% in premarket trading Monday following positive results from its FULCRUM-VT pivotal clinical trial for its vCLAS Ventricular Ablation System. The trial of 209 patients demonstrated 84% freedom from shock and 59% freedom from ventricular tachycardia recurrence, supporting the company's FDA Premarket Approval application. The results also showed reduced hospital readmission rates and meaningful de-escalation of amiodarone use.
Allegro NV appointed Stephan Crokaert as Chief Operating Officer to support the development of hydrocelin, a potential first-in-class injectable treatment for osteoarthritis, with plans to begin clinical trials in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.